Icon Group, a global leader in integrated cancer care, has announced a significant new agreement with Varian, a Siemens Healthineers company, involving an investment of more than USD $18.7 million to expand access to cutting-edge, world-class cancer treatment technology across the United Kingdom.

and follow Icon Group on LinkedIn at https://www.linkedin.com/company/icon-group

About Varian

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.

Icon and Varian’s global partnership

Icon Group and Varian have a long history of collaboration in delivering advanced cancer care across Australia, New Zealand, Asia, and now the UK. Icon clinicians and medical professionals are active members of Varian’s global AI and RapidArc Dynamic consortiums and are engaged in clinical research and product development initiatives worldwide.

The expanded partnership in the UK also builds on a five-year professional services and research agreement between Icon and Varian established in 2022 and highlights a shared commitment to innovation, access, and improved patient outcomes.

QR700024577

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626798284/en/